Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Merck Announces First-Quarter 2024 Financial Results
Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.”
US FDA approves ImmunityBio`s bladder cancer therapy
Merck, known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]).
Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat PAH, Merck has kicked off an educational campaign around the rare disease.
Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters.
Moderna jumps as vaccine shows benefit in head and neck cancer in early study
In December, when Merck revealed that Lynparza didn’t add benefits to Keytruda in certain non-small cell lung cancer (NSCLC) patients, the trial appeared to be a complete failure. Although the study itself is beyond salvaging, detailed data now raise some hope for the combination in the future.
Science and technology company Merck Tuesday said it has appointed Dhananjay Singh as the managing director of Merck Life Science in India.